Business Context and Reporting Period
Company: Assembly Biosciences, Inc. (ASMB)
Filing Type: Form 8-K (Current Report)
Date: December 8, 2025
Subject: Regulation FD Disclosure and Other Events regarding interim clinical trial results for investigational HSV helicase-primase inhibitors ABI-1179 and ABI-5366.
Key Financial Metrics
This filing is a non-financial current report. It does not contain revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Results
The Company announced interim results from Phase 1b studies for two candidates targeting recurrent genital herpes:
- ABI-1179 (Weekly Dosing - 50 mg):
- HSV-2 Shedding Rate: 98% reduction vs. placebo (p<0.01), exceeding the 80%-85% target.
- Genital Lesion Rate: 91% reduction vs. placebo (p<0.01).
- High Viral Load: Over 99% reduction vs. placebo.
- Safety: Well-tolerated; PK profile supports once-weekly dosing.
- ABI-5366 (Monthly Dosing Cohort):
- HSV-2 Shedding Rate: 76% reduction vs. placebo (p<0.01). Note: 89% of positive swabs occurred in the final two weeks as drug levels declined.
- Genital Lesion Rate: 88% reduction vs. placebo (p<0.01).
- High Viral Load: 81% reduction vs. placebo (p<0.01).
- ABI-5366 (Weekly Dosing - 350 mg - Previously Reported):
- HSV-2 Shedding Rate: 94% reduction vs. placebo (p=0.01).
- Genital Lesion Rate: 97% reduction vs. placebo (p<0.05).
Outlook, Management Commentary, and Risks
Management Commentary: The Company is progressing Phase 2 enabling activities for ABI-1179 in parallel with the completion of the Phase 1b study (which includes a third and potentially a fourth cohort). ABI-5366 is well-tolerated across regimens, with PK profiles supporting both once-weekly and potentially once-monthly dosing.
Risks and Contingencies: The filing notes that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability. Clinical development carries inherent risks, including the potential for future data to differ from interim results.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical tables and safety data.
- Confirm the timeline for the completion of the remaining Phase 1b cohorts for ABI-1179.
- Monitor upcoming announcements regarding the initiation of Phase 2 trials for ABI-1179.
- Review the specific pharmacokinetic data explaining the decline in drug levels for the monthly ABI-5366 cohort in the final two weeks.